ELSEVIER

Drug and Alcohol Dependence 60 (2000) 329–331

DRUG and ALCOHOL DEPENDENCE

www.elsevier.com/locate/drugalcdep

# Cumulative Author index

## Volumes 57–60 (2000)

Abood, M.E. **60**, 133
Adams, E.H. **57**, 7
Addy, R.C. **59**, 177
Adlaf, E.M. **60**, 97
Albery, I.P. **58**, 197
Alcorn, R. **59**, 189
Alemán-Valls, M.R. **59**, 295
Ali, S.F. **59**, 143
Alterman, A.I. **59**, 215
Alterman, A.I. **60**, 267
Amass, L. **58**, 143
Angelopoulos, E.K. **59**, 95
Anglin, M.D. **57**, 137
Anthony, J.C. **57**, 183
Anthony, J.C. **59**, 89
Anthony, J.C. **60**, 251
Anton, R.F. **60**, 161
Ator, N.A. **57**, 51
Aung, M.M. **60**, 133
Averill, P.M. **60**, 189
Aykaç-Toker, G. **58**, 77

Babb, D.A. **60**, 69
Badger, G.J. **60**, 259
Bailley, S.E. **60**, 189
Balldin, J. **57**, 255
Ball, S.A. **57**, 225
Balster, R.L. **58**, 1
Bammer, G. **58**, 173
Barber, J.P. **60**, 169
Bass, C.E. **60**, 113
Batlle, F. **59**, 223
Battisson, L. **58**, 173
Battjes, R.J. **57**, 81
Baumann, M.H. **59**, 143
Bearn, J. **59**, 183
Bearn, J. **60**, 207
Ben-Abdallah, A. **58**, 247
Benowitz, N.L. **60**, 13
Berggren, U. **57**, 255
Best, D. **60**, 319
Bickel, W.K. **58**, 27
Bickel, W.K. **60**, 259
Bienkowski, P. **60**, 199
Bigelow, G.E. **58**, 205
Bisaga, A. **59**, 1
Bishop, S. **60**, 169
Blaine, J. **59**, 63, 77
Blow, F.C. **58**, 43
Bobashev, G. **60**, 251
Bondarev, M. **57**, 1
Booth, R.E. **58**, 219
Bortone, L. **58**, 93
Brady, K.T. **59**, 277
Brady, K.T. **60**, 161
Brodsky, A. **60**, 221
Broers, B. **58**, 85
Broome, K.M. **57**, 113, 127
Brown, B.S. **57**, 137
Brown, M. **60**, 151
Brown, S. **60**, 69
Bucholz, K.K. **60**, 295
Bukstein, O.G. **59**, 173
Buntwal, N. **59**, 183

Cacciola, J.S. **59**, 215
Calay, Z. **58**, 77
Carboni, E. **58**, 93
Carmen del Río, M. **57**, 177
Carpenter, K.M. **59**, 63, 77
Carrieri, M.P. **60**, 51
Carrigan, M.H. **59**, 277
Carroll, K.M. **57**, 225
Casas, M. **59**, 223
Cedeño, M. **60**, 251
Cherek, D.R. **60**, 179
Chermack, S.T. **58**, 43
Chermack, S.T. **59**, 43
Childress, A.R. **59**, 33
Chioni, A. **59**, 95
Chitwood, D.D. **58**, 153, 219
Christo, G. **59**, 189
Chutuape, M.A. **57**, 211
Cicero, T.J. **57**, 7
Clapp, J.D. **60**, 19
Cnaan, A. **59**, 215
Coffey, S.F. **59**, 277
Cofrancesco, J. **60**, 311
Compton, W. **57**, 203
Compton, W.M. **58**, 215, 247
Cone, E.J. **58**, 205
Conte, G. **59**, 287
Copeland, A.L. **59**, 17
Copeland, J. **59**, 309
Copeland, J. **60**, 91
Corey, L.A. **57**, 69
Cornish, J.W. **59**, 33
Costantino, L. **60**, 121
Cottler, L.B. **57**, 203
Cottler, L.B. **58**, 247
Craddock, S.G. **57**, 99
Crits-Christoph, P. **60**, 169
Crome, I.B. **59**, 207
Crosby, H. **58**, 227
Crowley, T.J. **59**, 131
Crystal, S. **60**, 77
Cunningham, J.A. **59**, 211
Cunningham-Williams, R. **58**, 247

Dadds, M.R. **60**, 1
Daley, D. **60**, 169
Dansky, B.S. **59**, 277
Darke, S. **58**, 189
Darke, S. **60**, 141
Daskalopoulou, E.G. **59**, 95
Davis, K. **60**, 121
Davis, L. **59**, 43
Dawe, S. **60**, 1
Dawson, D.A. **59**, 235
Degenhardt, L. **57**, 247
de la Vega-Prieto, M.J. **59**, 295
Dellamonica, P. **60**, 51
Delva, J. **59**, 89
Delva, J. **60**, 251
Dennis, M.L. **58**, 259
De Risio, S. **59**, 287
de Wit, H. **59**, 251
Di Chiara, G. **58**, 93
DiClemente, C.C. **59**, 177
Dietz Trautman, K. **59**, 77
Dillon, P. **60**, 91
Dobs, A.S. **60**, 311
Doğru-Abbasoğlu, S. **58**, 77
Dolan, R.J. **60**, 207
Douglas Anglin, M. **57**, 151
Dudish-Poulsen, S. **57**, 239
Dukat, M. **60**, 121
Dumont, P. **58**, 85

Eber, M. **58**, 227
Egan, C. **60**, 121
Ehlers, C.L. **58**, 125
Ehlers, K.M. **59**, 131
Ehrman, R.N. **59**, 33
Epperson, L. **60**, 267
Etcheberrigaray, A. **59**, 223
Etheridge, R.M. **57**, 99

PII: S0376-8716(00)00202-7

Fahlke, C. **57**, 255
Farbiszewski, R. **57**, 61
Farren, C.K. **59**, 153
Fenton, L. **57**, 225
Fletcher, B.W. **57**, 81
Floyd, K. **60**, 319
Flynn, P.M. **57**, 167
Frackowiak, R.S.J. **60**, 207
France, C.P. **59**, 51
Franken, I.H.A. **59**, 305
Frankforter, T.L. **57**, 225
Friston, K.J. **60**, 207
Fudala, P.J. **60**, 29
Fujimura, R.K. **58**, 153
Fuller, B.E. **58**, 43
Furr, C.D.M. **59**, 89

Gallais, H. **60**, 51
Gallop, R. **60**, 169
Gariti, P. **60**, 267
Gastfriend, D.R. **60**, 169
Gatzonis, S.D. **59**, 95
Geller, A. **57**, 7
Geppetti, P. **60**, 13
Gessa, G.L. **60**, 39
Ghodse, A.H. **58**, 111
Giner, F. **58**, 85
Giua, C. **58**, 93
Glass, Y. **59**, 207
Glennon, R.A. **57**, 1
Glennon, R.A. **60**, 121
Gómez-Rodríguez, M.A. **59**, 295
González, G. **60**, 251
González, I. **58**, 159
González-Reimers, E. **59**, 295
Gossop, M. **57**, 89
Gossop, M. **58**, 165, 197
Gossop, M. **59**, 183
Gossop, M. **60**, 275
Goto, K. **58**, 67
Grabowski, J. **59**, 43
Grabowski, J. **60**, 189
Graham, G. **58**, 153
Grant, B.F. **60**, 287
Greeley, J.D. **57**, 29
Greenwald, M.K. **59**, 261
Grella, B. **60**, 121
Grella, C.E. **57**, 137, 151
Griffin, G. **60**, 133
Griffin, M.L. **60**, 169
Griffith, J.D. **58**, 55
Griffiths, P. **58**, 197
Griffiths, R.R. **57**, 51
Grimm, J.W. **57**, 41
Gruber, K. **57**, 211

Habrat, B. **60**, 199
Hall, W. **57**, 247
Hall, W. **59**, 309
Hameedi, F.A. **59**, 153
Harnett, P.H. **60**, 1
Hasin, D.S. **59**, 63, 77
Hatsukami, D.K. **57**, 239
Hatsukami, D.K. **60**, 69
Hatzimanolis, J. **57**, 261
Heishman, S.J. **60**, 29
Hendriks, V.M. **59**, 305
Hennen, J. **58**, 35
Henningfield, J.E. **60**, 29
Herron, J. **60**, 161
Hettema, J.M. **57**, 69
Higgins, S.T. **58**, 103
Hock, C. **57**, 23
Hoffman, J.A. **58**, 227
Hollister, L.E. **58**, 3
Hong, S.-S. **60**, 121
Horton, J. **57**, 203
Howlett, M. **58**, 111
Hser, Y.-I. **57**, 137, 151
Hsieh, S.-C. **57**, 137
Hubbard, R.L. **57**, 99, 167
Huffman, J.W. **60**, 133
Hug, I. **57**, 23

Iguchi, M.Y. **57**, 193
Ikemoto, S. **58**, 67
Inciardi, J.A. **57**, 7
Ishiguro, T. **58**, 67
Ivis, F.J. **60**, 97

Jacob, P., III **60**, 13
Jatlow, P. **59**, 153
Javier Alvarez, F. **57**, 177
Joe, G.W. **57**, 113, 127
Johnson, R.E. **60**, 29
Jones, H.E. **60**, 29
Joshi, V. **57**, 151

Kajdasz, D.K. **60**, 161
Kamali, F. **59**, 125
Kamien, J.B. **58**, 143
Kaminska, E. **60**, 303
Katz, E. **58**, 205
Kaufman, M.J. **58**, 35
Kaye, S. **58**, 189
Keel, C. **60**, 133
Kendler, K.S. **57**, 69
Kilaru, U. **59**, 43
Kilpatrick, B. **58**, 111
Klein, H. **58**, 227
Kokkevi, A. **58**, 181
Koros, E. **60**, 199
Kosten, T.R. **59**, 153
Kostowski, W. **60**, 199
Kostrzewa, A. **60**, 303
Kristiansen, P.L. **57**, 167
Krupski, A. **60**, 151
Kruzich, P.J. **57**, 41
Kukes, T.J. **58**, 35
Kukwa, A. **60**, 199
Kwiatkowski, C.F. **58**, 219

Ladewig, D. **57**, 23
Lane, S.D. **60**, 179
Lázaro, M.I. **58**, 159
Lepeu, G. **60**, 51
Leukefeld, C. **58**, 237
Levin, J.M. **58**, 35
Lexau, B. **57**, 239
Logan, T.K. **58**, 237
London, L. **59**, 199
Longhi, D. **60**, 151
Luchansky, B. **60**, 151
Lukas, S. **59**, 165
Lukas, S.E. **58**, 35
Lykouras, L. **57**, 261
Lynch, K.G. **59**, 173
Lynskey, M. **57**, 247

MacDonald, B. **58**, 259
Madden, G.J. **60**, 259
Malcolm, R. **60**, 161
Manning, V. **60**, 319
Mantouvalos, V. **59**, 95
Maremmani, I. **60**, 39
Markianos, M. **57**, 261
Marsden, J. **57**, 89
Marsden, J. **58**, 165
Marsden, J. **60**, 275
Martin, B.R. **60**, 113, 133
Martin, C.S. **59**, 173
Martin, S. **59**, 223
Martinez-Riera, A. **59**, 295
Mattson, M.V. **60**, 121
McCaffrey, D. **57**, 193
McCoy, C.B. **58**, 153
McGill, T. **60**, 55
McKay, J.R. **59**, 215
McNamara, C. **60**, 55
M. Dürsteler, K. **57**, 23
Mendelson, J.H. **58**, 35
Merikle, E.P. **59**, 215
Metsch, L. **58**, 153
Michael, M. **60**, 55
Miele, G.M. **59**, 63, 77
Mikolajczak, P. **60**, 303
Mikulich, S.K. **58**, 143
Mikulich, S.K. **59**, 131
Milby, J.B. **60**, 55
Milena, A. **59**, 295
Mino, A. **58**, 85
Moerschbaecher, J.M. **59**, 51
Morral, A.R. **57**, 193
Morris, J.S. **60**, 207
Moussas, G. **57**, 261
Müller-Spahn, F. **57**, 23
Mulvaney, F.D. **59**, 215
Mulvaney, F.D. **60**, 267
Muñoz, A. **57**, 7
Mutlu-Türkoğlu, Ü. **58**, 77

Neale, J. **58**, 117
Nelson, D. **57**, 239

Nemtsov, A.V. **58**, 133
Newbury-Birch, D. **59**, 125
Nich, C. **57**, 225
Norrby, A. **57**, 255
Nuro, K.F. **57**, 225

Obadia, Y. **60**, 51
O'Brien, C.P. **59**, 33
Odum, A.L. **60**, 259
Ogborne, A. **60**, 315
Okulicz-Kozaryn, I. **60**, 303
Onken, L.S. **60**, 169
Orozco, S. **59**, 165
Öztezcan, S. **58**, 77

Page, J.B. **58**, 153
Pani, P.P. **60**, 39
Parrott, A.C. **60**, 105
Peele, S. **60**, 221
Pentel, P.R. **57**, 239
Pentel, P.R. **60**, 69
Pérez de los Cobos, J. **59**, 223
Pérez-Manzano, J.L. **59**, 295
Perritt, R. **58**, 259
Peters, R. **60**, 91
Petronis, K.R. **57**, 183
Petry, N.M. **58**, 9, 27
Phelps, D.L. **60**, 295
Pirastu, R. **60**, 39
Politikou, K. **58**, 181
Pollock, N.K. **59**, 173
Popik, P. **59**, 1
Porto, J.V. **57**, 167
Pozzi, G. **59**, 287
Preston, K.L. **58**, 205

Queraltó, J.M. **59**, 223

Rasch, R.F.R. **58**, 259
Rawaf, S. **60**, 319
Rehm, J. **60**, 97
Reilly, M. **59**, 43
Renaud, F.L. **58**, 159
Renshaw, P.F. **58**, 35
Rivers, J.E. **58**, 153
Roark, R.R. **58**, 55
Robbins, S.J. **59**, 33
Robles, E. **58**, 205
Rolfe, A. **57**, 89
Rolfe, A. **58**, 165
Rolfe, A. **60**, 275
Roll, J. **59**, 43
Roll, J.M. **58**, 103
Room, R. **60**, 249
Rosen, M.A. **59**, 153
Ross, J. **60**, 141
Rothfleisch, J.M. **60**, 189
Rothman, R.B. **59**, 143
Rounds-Bryant, J.L. **57**, 99
Rounsaville, B.J. **57**, 225
Rowan-Szal, G.A. **58**, 55
Rowley, J. **60**, 319
Rustay, N. **57**, 41
Rutherford, M.J. **59**, 215

Sambamoorthi, U. **60**, 77
Santolaria, F. **59**, 295
Sarr, M. **60**, 295
Sattler-Mayr, J. **57**, 23
Sayre, S.L. **60**, 189
Schmitz, J.M. **60**, 189
Schnoll, S.H. **57**, 7
Schumacher, J.E. **60**, 55
Scinska, A. **60**, 199
Sedgwick, P. **58**, 111
See, R.E. **57**, 41
Segal, D. **58**, 153
Seifritz, E. **57**, 23
Sell, L.A. **60**, 207
Senay, E.C. **57**, 7
Shah Jr, N. **60**, 311
Shah, S.M. **58**, 153
Shapshak, P. **58**, 153
Shillington, A.M. **60**, 19
Showalter, V.M. **60**, 133
Siafakas, A. **59**, 95
Sifry, R.L. **57**, 225
Silverman, K. **58**, 205
Silvester, K.R. **59**, 51
Simpson, D.D. **57**, 113, 127
Simpson, D.D. **58**, 55
Sisk, E. **60**, 105
Skrzydlewska, E. **57**, 61
Slawecki, C.J. **58**, 125
Smart, R.G. **60**, 315
Smith, C. **60**, 121
Smith Cockerham, M. **59**, 63, 77
Sofuoglu, M. **57**, 239
Sofuoglu, M. **60**, 69
Somes, C. **58**, 125
Sorensen, J.L. **59**, 17
Spire, B. **60**, 51
Spitznagel, E.L. **58**, 247
Spurrell, S. **59**, 189
Staiger, P. **60**, 1
Staiger, P.K. **57**, 29
Stark, K. **60**, 151
Stefanis, C. **58**, 181
Stewart, D. **57**, 89
Stewart, D. **58**, 165
Stewart, D. **60**, 275
Stitzer, M.L. **57**, 211
Stitzer, M.L. **58**, 205
Stitzer, M.L. **59**, 261
Stohler, R. **57**, 23
Störmer, R. **57**, 23
Stotts, A.L. **60**, 189
Strang, J. **58**, 197
Strang, J. **59**, 183
Strang, J. **60**, 319
Sunjic, S. **60**, 141
Surratt, H.L. **58**, 267
Swift, W. **59**, 309

Tagliamonte, A. **60**, 39
Tang, A. **60**, 311
Tarter, R.E. **59**, 101
Teitler, M. **60**, 121
Tejero, A. **59**, 223
Terzidou, M. **58**, 181
Tomassini, N. **58**, 159
Tourian, K.A. **59**, 215
Trautman, K.D. **59**, 63
Trujols, J. **59**, 223
Turner, J.J.D. **60**, 105

Usdan, S. **60**, 55
Uysal, M. **58**, 77

Vanyukov, M.M. **59**, 101
Velasquez, M.M. **59**, 177
Villafuerte, R.A. **58**, 35
Vlahov, D. **60**, 51

Wachtel, S.R. **59**, 251
Wahlstrom, J.T. **60**, 311
Walkup, J. **60**, 77
Wallace, D. **60**, 55
Wallace, S.D. **57**, 29
Ward, J. **58**, 173
Warner, L.A. **60**, 77
Weatherby, N. **58**, 153
Wechsberg, W.M. **58**, 259
Weerts, E.M. **57**, 51
Weisen, C.A. **58**, 259
Weiss, R.D. **60**, 169
White, M. **59**, 125
Whitmore, E.A. **59**, 131
Wiktorowicz, K. **60**, 303
Wilson, S. **58**, 173
Winsauer, P.J. **59**, 51
Woods, S. **59**, 153
Woody, G.E. **57**, 7
Wu, M.-J. **60**, 133

Yang, B. **60**, 133
Yang, J. **58**, 153
Young, R. **57**, 1
Yui, K. **58**, 67

Zachrisson, O. **57**, 255
Zador, D. **60**, 141
Zevin, S. **60**, 13
Zournas, C. **59**, 95

ELSEVIER

Drug and Alcohol Dependence 60 (2000) 333–345

DRUG and ALCOHOL DEPENDENCE

www.elsevier.com/locate/drugalcdep

# Cumulative Subject index

## Volumes 57–60 (2000)

**Abstinence**; Dopamine; Nicotine; Naloxone; Nucleus accumbens; Prefrontal cortex **58**, 93

**Abstinence**; Ethanol; Associative learning; Event related potentials; Neurophysiology **58**, 125

**Abstinence initiation**; Voucher-based reinforcement; Cocaine abuse; Urinalysis; Methadone patients; Contingency contracting **58**, 205

**Abuse**; Anabolic-androgenic steroids; Dependence; Women **60**, 91

**Abuse**; Drug self-administration; Propofol; Methohexital; Cocaine; Feeding; Primates **57**, 51

**Accident involvement**; Illicit drugs; Impaired driving; Impairment beliefs **58**, 197

**Acculturation**; Drug use; Ethnic; Gender; Aggression **59**, 165

**Addiction**; Buprenorphine; Methadone maintenance; Heroin **60**, 39

**Addiction**; Ibogaine; MK-801; Dopamine; Corticosterone; Prolactin **59**, 143

**Addiction**; Nicotine; Cotinine; Metabolism; Pharmacokinetics; Tobacco; Pharmacodynamics **60**, 13

**Addiction severity index**; Opioids; Detoxification **58**, 85

**Adolescent drug use**; Frequent smoking; Frequent drinking; Risk factors; Substance use careers **60**, 319

**Adolescents**; Conduct disorder; Substance use; Attention-deficit hyperactivity disorder; Major depressive disorder; Gender **59**, 131

**Adolescents**; Diagnostic interviews; DSM-IV; SCID; Substance use disorders **59**, 173

**Adolescents**; Substance use reports; Agreement rates; Reliability; Surveys **60**, 19

**Adrenergic receptors**; Self-administration; Carvedilol; Cocaine; Cardiovascular effects **60**, 69

**Affinity**; Cannabinoid; Cannabinoid receptors; Radioligand binding; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

**African-American**; Alcohol; Crack; HIV; Sexual risk **58**, 259

**Aftercare**; Drug abuse treatment; Outpatient treatment; Heroin; Cocaine; Contingency management; Housing; Employment **57**, 211

**Age of onset**; Substance use disorders; Personality disorders; Psychopathology; Comorbidity **59**, 305

**Aggression**; Acculturation; Drug use; Ethnic; Gender **59**, 165

**Aggression**; Relationships; Alcohol; Drugs; Violence **58**, 43

**Agreement rates**; Substance use reports; Reliability; Adolescents; Surveys **60**, 19

**AIDS**; HIV prevention; Drug abuse; Antisocial personality; Depression; Comorbidity **58**, 247

**AIDS**; Injecting drug user; Blood; Needle/syringe; Paraphernalia; Shooting gallery; HIV-1 RNA load **58**, 153

**Alcohol abuse**; Alcohol dependence; Dependence symptoms; Diagnosis; Nosology **60**, 295

**Alcohol abuse**; Alcohol dependence; Subtypes of alcohol dependence; Subtypes of alcohol abuse; Nosology **60**, 287

**Alcohol**; African-American; Crack; HIV; Sexual risk **58**, 259

**Alcohol**; Aggression; Relationships; Drugs; Violence **58**, 43

**Alcohol**; Cocaine; Pergolide; Clinical trial; Pharmacotherapy **60**, 161

**Alcohol consumption**; CAGE; MAST; DOP system; Farm workers; South Africa **59**, 199

**Alcohol consumption**; Moderate drinking; Psychosocial models; Mental health; Cognitive performance; Psychological benefits **60**, 221

**Alcohol consumption *per capita***; Student drinking; Cross culture comparisons **60**, 315

**Alcohol consumption**; Russia; Registered and unregistered alcohol consumption; Consequences of alcohol consumption **58**, 133

**Alcohol**; Cue exposure; Dependent drinkers; Generalisation; Relapse prevention **57**, 29

**Alcohol dependence**; Alcohol abuse; Dependence symptoms; Diagnosis; Nosology **60**, 295

**Alcohol dependence**; Alcohol abuse; Subtypes of alcohol dependence; Subtypes of alcohol abuse; Nosology **60**, 287

**Alcoholic patients**; Dopamine receptor responsivity; Detoxification **57**, 261

PII: S0376-8716(00)00203-9

**Alcoholics anonymous**; Self-help groups; Cocaine; Treatment; Drug abuse **60**, 169

**Alcohol**; Illegal drugs; Road traffic accidents; Spain **57**, 177

**Alcoholism**; Malnutrition; Social problems; Feeding habits; Liver disease; DEXA **59**, 295

**Alcohol**; Medical students; Illicit drugs; Stress; Personality **59**, 125

**Alcohol**; NMDA receptor antagonists; Opiates; Psychostimulants; Pharmacotherapy **59**, 1

**Alcohol**; Substance misuse; Treatment outcomes; Evaluation; Clinical audit **59**, 189

**Alcohol withdrawal**; Clonidine; Growth hormone; Noradrenergic activity **57**, 255

**Alternate-day dosing**; Buprenorphine; Buprenorphine–naloxone; Heroin treatment; Human; Methadone treatment **58**, 143

**Alternating logistic regression**; Epidemiology; Drug use; Panama; Clustering; Schools **60**, 251

**Aminoalkylindoles**; Cannabinoid; Cannabinoid receptors; Radioligand binding; Affinity; Cannabimimetic indoles **60**, 133

**Amphetamine**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Amphetamines**; Heroin; Harms; Injecting drug use **58**, 189

**Anabolic-androgenic steroids**; Abuse; Dependence; Women **60**, 91

**Analgesia**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

**Antinociception**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

**Antisocial behavior**; Risk taking; Drug abuse; Laboratory task **60**, 179

**Antisocial personality**; HIV prevention; Drug abuse; AIDS; Depression; Comorbidity **58**, 247

**Assessment**; DSM-IV dependence; Severity; Reliability; Validity; Outcome measures **59**, 63

**Assessment**; Substance Dependence Severity Scale; Predictive validity **59**, 77

**Associative learning**; Ethanol; Abstinence; Event related potentials; Neurophysiology **58**, 125

**Attention-deficit hyperactivity disorder**; Conduct disorder; Substance use; Major depressive disorder; Gender; Adolescents **59**, 131

**AUDIT**; Survey methods; Epidemiology **60**, 97

**Australia**; Cannabis; Dependence; Follow-up **59**, 309

**Autoremission**; Natural recoveries; Drug use; Service utilization **59**, 211

**Baseline predictors**; Cocaine dependence; Treatment outcome **59**, 215

**Behavioral phenotype**; Substance abuse; Genotype–environment interaction **59**, 101

**Benzodiazepine**; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Seizures; Side effects; Withdrawal **59**, 95

**Benzodiazepine receptors**; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; PI hydrolysis **60**, 121

**Bitter**; Ethanol; Taste perception; Sweet; Sour; Humans **60**, 199

**Blockade**; Nalmefene; Morphine; Subjective effects; Pharmacology **60**, 29

**Blood**; Injecting drug user; Needle/syringe; Paraphernalia; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

**Blood pressure**; Cocaine; Crack cocaine; Cardiovascular response; Heart rate; Toxicity **57**, 239

**Brain imaging**; Cocaine; Drug history; Intravenous; Safety **58**, 35

**Brazil**; Cocaine; HIV **58**, 267

**Buprenorphine**; Alternate-day dosing; Buprenorphine–naloxone; Heroin treatment; Human; Methadone treatment **58**, 143

**Buprenorphine**; HIV; Injection drug users; Drug maintenance treatment; Viral load **60**, 51

**Buprenorphine**; Hostility; Retention; Early termination; Gender differences; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

**Buprenorphine**; Methadone maintenance; Heroin; Addiction **60**, 39

**Buprenorphine–naloxone**; Alternate-day dosing; Buprenorphine; Heroin treatment; Human; Methadone treatment **58**, 143

**Buprenorphine**; Opioid dependence; Treatment; Thrice-weekly dosing **59**, 223

**CAGE**; Alcohol consumption; MAST; DOP system; Farm workers; South Africa **59**, 199

**Calcium sequestration**; Cocaine; Ethanol; Hepatotoxicity; Lipid peroxidation **58**, 77

**Cannabimimetic indoles**; Cannabinoid; Cannabinoid receptors; Radioligand binding; Affinity; Aminoalkylindoles **60**, 133

**Cannabinoid**; Cannabinoid receptors; Radioligand binding; Affinity; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

**Cannabinoid**; Delta-9-tetrahydrocannabinol; $\Delta^9$-THC; Tolerance; Time course **60**, 113

**Cannabinoid**; Dronabinol; Marijuana; Opioid; THC **59**, 251

**Cannabinoid receptors**; Cannabinoid; Radioligand binding; Affinity; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

**Cannabis**; Dependence; Follow-up; Australia **59**, 309

**β-carbolines**; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**Cardiovascular effects**; Adrenergic receptors; Self-administration; Carvedilol; Cocaine **60**, 69

**Cardiovascular response**; Cocaine; Crack cocaine; Blood pressure; Heart rate; Toxicity **57**, 239

**Carvedilol**; Adrenergic receptors; Self-administration; Cocaine; Cardiovascular effects **60**, 69

**Cathine**; Ephedrine; Norephedrine; Pseudoephedrine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Cigarette smoking**; Contingency-management; Substance abuse; Relapse; Schedules of reinforcement; Treatment **58**, 103

**Circadian cycle**; Ethanol preference; Rats; Lymphocyte subsets; Cytometry **60**, 303

**Clinical audit**; Substance misuse; Alcohol: Treatment outcomes; Evaluation **59**, 189

**Clinical trial**; Cocaine; Pergolide; Alcohol; Pharmacotherapy **60**, 161

**Clonidine**; Alcohol withdrawal; Growth hormone; Noradrenergic activity **57**, 255

**Clonidine**; Opiate withdrawal; Naltrexone; Trazodone **59**, 287

**Clozapine**; Cocaine; Drug interactions; Humans **59**, 153

**Clustering**; Epidemiology; Drug use; Panama; Alternating logistic regression; Schools **60**, 251

**Cocaine abuse**; Voucher-based reinforcement; Abstinence initiation; Urinalysis; Methadone patients; Contingency contracting **58**, 205

**Cocaine addiction**; Drug treatment costs; Treatment benefits; Crime costs; Cost-benefit **57**, 167

**Cocaine**; Adrenergic receptors; Self-administration; Carvedilol; Cardiovascular effects **60**, 69

**Cocaine**; Brain imaging; Drug history; Intravenous; Safety **58**, 35

**Cocaine**; Brazil; HIV **58**, 267

**Cocaine**; Calcium sequestration; Ethanol; Hepatotoxicity; Lipid peroxidation **58**, 77

**Cocaine**; Clozapine; Drug interactions; Humans **59**, 153

**Cocaine**; Crack cocaine; Cardiovascular response; Blood pressure; Heart rate; Toxicity **57**, 239

**Cocaine dependence**; Baseline predictors; Treatment outcome **59**, 215

**Cocaine dependence**; Cue reactivity; Mood state; Craving; Cocaine use **59**, 33

**Cocaine dependence**; Major depression; Dual-diagnosis; Substance abuse comorbidity; Drug abuse **60**, 189

**Cocaine**; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Contingency management; Housing; Employment **57**, 211

**Cocaine**; Drug self-administration; Propofol; Methohexital; Feeding; Primates; Abuse **57**, 51

**Cocaine**; HIV; Prevention initiatives **58**, 215

**Cocaine**; Pergolide; Alcohol; Clinical trial; Pharmacotherapy **60**, 161

**Cocaine**; Self-administration; Conditioned reinforcement; Extinction; Relapse **57**, 41

**Cocaine**; Self-help groups; Alcoholics anonymous; Treatment; Drug abuse **60**, 169

**Cocaine**; Substance abuse; Treatment; Homeless; Dual diagnosis **60**, 55

**Cocaine use**; Cue reactivity; Cocaine dependence; Mood state; Craving **59**, 33

**Cocaine use**; Drug treatment history; Treatment process; Treatment outcome; Social support; Environmental context **57**, 137

**Cocaine**; Withdrawal; Human; Outpatient; Drug dependence **59**, 277

**Cognitive performance**; Moderate drinking; Psychosocial models; Mental health; Alcohol consumption; Psychological benefits **60**, 221

**Cognitive processes**; Reinforcers; Sequence **59**, 51

**Comorbidity**; Age of onset; Substance use disorders; Personality disorders; Psychopathology **59**, 305

**Comorbidity**; HIV prevention; Drug abuse; AIDS; Antisocial personality; Depression **58**, 247

**Compassionate use**; Marijuana, medical uses; Legal aspects; Indications; Questionnaire **58**, 3

**Compliance**; Contingency management; Incentives; Vouchers; Medication management; Substance abuse treatment **58**, 9

**Concordance**; Urinalysis; Self-report; Validity; Methadone **59**, 43

**Conditioned reinforcement**; Cocaine; Self-administration; Extinction; Relapse **57**, 41

**Conduct disorder**; Substance use; Attention-deficit hyperactivity disorder; Major depressive disorder; Gender; Adolescents **59**, 131

**Consequences of alcohol consumption**; Russia; Alcohol consumption; Registered and unregistered alcohol consumption **58**, 133

**Contingency contracting**; Voucher-based reinforcement; Abstinence initiation; Cocaine abuse; Urinalysis; Methadone patients **58**, 205

**Contingency-management**; Cigarette smoking; Substance abuse; Relapse; Schedules of reinforcement; Treatment **58**, 103

**Contingency management**; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Cocaine; Housing; Employment **57**, 211

**Contingency management**; Incentives; Vouchers; Medication management; Compliance; Substance abuse treatment **58**, 9

**Contingency management**; Treatment efficacy; Methadone maintenance; Meta-analysis **58**, 55

**Controlled Substances Act**; Tramadol HCl; Drug abuse; Drug dependence; Ultram®; Postmarketing surveillance **57**, 7

**Convulsive status epilepticus**; Benzodiazepine; Flunitrazepam; Lorazepam; Seizures; Side effects; Withdrawal **59**, 95

**Cortical hemoglobin deoxygenation**; Heroin; Methadone; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

**Corticosterone**; Ibogaine; MK-801; Dopamine; Prolactin; Addiction **59**, 143

**Cost-benefit**; Drug treatment costs; Treatment benefits; Crime costs; Cocaine addiction **57**, 167

**Cost-benefit model**; DATOS; Treatment process **57**, 81

**Cotinine**; Nicotine; Metabolism; Pharmacokinetics; Addiction; Tobacco; Pharmacodynamics **60**, 13

**Counseling**; Drug treatment; Treatment process; Self-help groups; Retention **57**, 99

**Crack**; African-American; Alcohol; HIV; Sexual risk **58**, 259

**Crack cocaine**; Cocaine; Cardiovascular response; Blood pressure; Heart rate; Toxicity **57**, 239

**Crack**; HIV; Injection drug user; Sex risk **58**, 219

**Crack**; IDUs; HIV; Women **58**, 227

**Crack users**; HIV **58**, 237

**Craving**; Cue reactivity; Cocaine dependence; Mood state; Cocaine use **59**, 33

**Crime costs**; Drug treatment costs; Treatment benefits; Cocaine addiction; Cost-benefit **57**, 167

**Crime reduction**; Heroin; Treatment outcome **58**, 165

**Cross culture comparisons**; Student drinking; Alcohol consumption *per capita* **60**, 315

**Cue exposure**; Alcohol; Dependent drinkers; Generalisation; Relapse prevention **57**, 29

**Cue**; Opiate dependence; Heroin; Neuroimaging **60**, 207

**Cue reactivity**; Cocaine dependence; Mood state; Craving; Cocaine use **59**, 33

**Cytometry**; Ethanol preference; Rats; Lymphocyte subsets; Circadian cycle **60**, 303

**DATOS**; Treatment process; Cost-benefit model **57**, 81

**DATOS**; Treatment process; Therapeutic engagements; Treatment retention; Motivation **57**, 113

**Delay discounting**; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Risky injection **60**, 259

**Delay discounting**; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

**Delta-9-tetrahydrocannabinol**; $\Delta^9$-THC; Cannabinoid; Tolerance; Time course **60**, 113

**Dependence**; Anabolic-androgenic steroids; Abuse; Women **60**, 91

**Dependence**; Cannabis; Follow-up; Australia **59**, 309

**Dependence**; Morphine; Tolerance; Macrophages; Phagocytosis; Immunology **58**, 159

**Dependence symptoms**; Alcohol dependence; Alcohol abuse; Diagnosis; Nosology **60**, 295

**Dependent drinkers**; Alcohol; Cue exposure; Generalisation; Relapse prevention **57**, 29

**Depression**; HIV prevention; Drug abuse; AIDS; Antisocial personality; Comorbidity **58**, 247

**Detoxification**; Dopamine receptor responsivity; Alcoholic patients **57**, 261

**Detoxification**; Opioids; Addiction severity index **58**, 85

**DEXA**; Alcoholism; Malnutrition; Social problems; Feeding habits; Liver disease **59**, 295

**Diagnosis**; Alcohol dependence; Alcohol abuse; Dependence symptoms; Nosology **60**, 295

**Diagnosis**; Reliability; Substance use disorders; Race **57**, 203

**Diagnostic interviews**; Adolescents; DSM-IV; SCID; Substance use disorders **59**, 173

**1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM)**; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**Dimethyltryptamine (DMT)**; β-carbolines; Harmaline; Harmine; Hallucinogens; 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**Dopamine**; Ibogaine; MK-801; Corticosterone; Prolactin; Addiction **59**, 143

**Dopamine**; Nicotine; Naloxone; Abstinence; Nucleus accumbens; Prefrontal cortex **58**, 93

**Dopamine receptor responsivity**; Alcoholic patients; Detoxification **57**, 261

**Dopamine receptors**; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**DOP system**; Alcohol consumption; CAGE; MAST; Farm workers; South Africa **59**, 199

**Drinking**; Risk factor; Sustained smoking **59**, 235

**Dronabinol**; Cannabinoid; Marijuana; Opioid; THC **59**, 251

**Drug abuse**; Cocaine dependence; Major depression; Dual-diagnosis; Substance abuse comorbidity **60**, 189

**Drug abuse**; Delay discounting; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

**Drug abuse**; Drug dependence; Heroin; Opiate dependence; Self-report; Urine testing **58**, 111

**Drug abuse**; HIV/AIDS; Methadone maintenance treatment; Medicaid **60**, 77

**Drug abuse**; HIV prevention; AIDS; Antisocial personality; Depression; Comorbidity **58**, 247

**Drug abuse**; Risk taking; Antisocial behavior; Laboratory task **60**, 179

**Drug abuse**; Self-help groups; Alcoholics anonymous; Cocaine; Treatment **60**, 169

**Drug abuse**; Tramadol HCl; Drug dependence; Ultram®; Postmarketing surveillance; Controlled Substances Act **57**, 7

**Drug Abuse Treatment Outcome Studies**; Treatment engagement; Motivation; Program differences **57**, 127

**Drug abuse treatment**; Outpatient treatment; Aftercare; Heroin; Cocaine; Contingency management; Housing; Employment **57**, 211

**Drug and alcohol abuse**; Twin study; Genetics **57**, 69

**Drug dependence**; Cocaine; Withdrawal; Human; Outpatient **59**, 277

**Drug dependence**; Drug abuse; Heroin; Opiate dependence; Self-report; Urine testing **58**, 111

**Drug dependence**; Tramadol HCl; Drug abuse; Ultram®; Postmarketing surveillance; Controlled Substances Act **57**, 7

**Drug history**; Brain imaging; Cocaine; Intravenous; Safety **58**, 35

**Drug interactions**; Clozapine; Cocaine; Humans **59**, 153

**Drug maintenance treatment**; HIV; Injection drug users; Viral load; Buprenorphine **60**, 51

**Drugs**; Aggression; Relationships; Alcohol; Violence **58**, 43

**Drug self-administration**; Propofol; Methohexital; Cocaine; Feeding; Primates; Abuse **57**, 51

**Drug treatment costs**; Treatment benefits; Crime costs; Cocaine addiction; Cost-benefit **57**, 167

**Drug treatment history**; Treatment process; Treatment outcome; Social support; Environmental context; Cocaine use **57**, 137

**Drug treatment**; Treatment process; Counseling; Self-help groups; Retention **57**, 99

**Drug use**; Acculturation; Ethnic; Gender; Aggression **59**, 165

**Drug use**; Epidemiology; Panama; Alternating logistic regression; Clustering; Schools **60**, 251

**Drug use**; Epidemiology; Regression; Stimulants **59**, 89

**Drug use frequency underreporting**; Monte Carlo models; Hardcore drug use; Occasional drug use; Self-report; Methadone maintenance clients **57**, 193

**Drug use history**; Young adults; Treatment career; Self-efficacy; Reference group **57**, 151

**Drug use**; Natural recoveries; Autoremission; Service utilization **59**, 211

**Drug use**; Overdose; Methadone; Treatment; Suicide **58**, 117

**DSM-IV**; Adolescents; Diagnostic interviews; SCID; Substance use disorders **59**, 173

**DSM-IV dependence**; Severity; Assessment; Reliability; Validity; Outcome measures **59**, 63

**DSM-IV**; Smokers; Psychiatric diagnosis; Patch treatment; Mental disorder **60**, 267

**Dual-diagnosis**; Cocaine dependence; Major depression; Substance abuse comorbidity; Drug abuse **60**, 189

**Dual diagnosis**; Substance abuse; Cocaine; Treatment; Homeless **60**, 55

**Early termination**; Hostility; Retention; Gender differences; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

**Ecstasy**; MDMA; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

**Employment**; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Cocaine; Contingency management; Housing **57**, 211

**Employment**; Washington State; Treatment **60**, 151

**Endocrinology**; Testosterone; HIV status; Injection drug use **60**, 311

**Endogenous opioids**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Analgesia; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

**Environmental context**; Drug treatment history; Treatment process; Treatment outcome; Social support; Cocaine use **57**, 137

**Ephedra**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Herbal dietary supplements; Thermogenic agents **57**, 1

**Ephedrine**; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Epidemiologic factors**; Logistic models; Residential mobility; Socioeconomic factors; Space-time clustering **57**, 183

**Epidemiology**; AUDIT; Survey methods **60**, 97

**Epidemiology**; Drug use; Panama; Alternating logistic regression; Clustering; Schools **60**, 251

**Epidemiology**; Drug use; Regression; Stimulants **59**, 89

**Erythrocytes**; *N*-acetylcysteine; Methanol-induced injury; Liver; Serum **57**, 61

**Ethanol**; Abstinence; Associative learning; Event related potentials; Neurophysiology **58**, 125

**Ethanol**; Calcium sequestration; Cocaine; Hepatotoxicity; Lipid peroxidation **58**, 77

**Ethanol preference**; Rats; Lymphocyte subsets; Cytometry; Circadian cycle **60**, 303

**Ethanol**; Taste perception; Bitter; Sweet; Sour; Humans **60**, 199

**Ethnic**; Acculturation; Drug use; Gender; Aggression **59**, 165

**Evaluation**; Substance misuse; Alcohol; Treatment outcomes; Clinical audit **59**, 189

**Event related potentials**; Ethanol; Abstinence; Associative learning; Neurophysiology **58**, 125

**Exclusion criteria**; Project MATCH; Treatment matching; Generalizability **59**, 177

**Extinction**; Cocaine; Self-administration; Conditioned reinforcement; Relapse **57**, 41

**Farm workers**; Alcohol consumption; CAGE; MAST; DOP system; South Africa **59**, 199

**Feeding**; Drug self-administration; Propofol; Methohexital; Cocaine; Primates; Abuse **57**, 51

**Feeding habits**; Alcoholism; Malnutrition; Social problems; Liver disease; DEXA **59**, 295

**Flashbacks**; Methamphetamine psychosis; Stressful experiences; Norepinephrine; 3-methoxytyramine **58**, 67

**Flunitrazepam**; Benzodiazepine; Convulsive status epilepticus; Lorazepam; Seizures; Side effects; Withdrawal **59**, 95

**Follow-up**; Cannabis; Dependence; Australia **59**, 309

**Frequent drinking**; Frequent smoking; Risk factors; Adolescent drug use; Substance use careers **60**, 319

**Frequent smoking**; Frequent drinking; Risk factors; Adolescent drug use; Substance use careers **60**, 319

**Gender**; Acculturation; Drug use; Ethnic; Aggression **59**, 165

**Gender**; Conduct disorder; Substance use; Attention-deficit hyperactivity disorder; Major depressive disorder; Adolescents **59**, 131

**Gender differences**; Hostility; Retention; Early termination; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

**Generalisation**; Alcohol; Cue exposure; Dependent drinkers; Relapse prevention **57**, 29

**Generalizability**; Project MATCH; Treatment matching; Exclusion criteria **59**, 177

**Genetics**; Drug and alcohol abuse; Twin study **57**, 69

**Genotype–environment interaction**; Substance abuse; Behavioral phenotype **59**, 101

**Greece**; High-school students; Substance use; Trends **58**, 181

**Growth hormone**; Alcohol withdrawal; Clonidine; Noradrenergic activity **57**, 255

**Hallucinogens**; β-carbolines; Harmaline; Harmine; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**Hardcore drug use**; Drug use frequency underreporting; Monte Carlo models; Occasional drug use; Self-report; Methadone maintenance clients **57**, 193

**Harmaline**; β-carbolines; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**Harmine**; β-carbolines; Harmaline; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**Harms**; Heroin; Amphetamines; Injecting drug use **58**, 189

**Heart rate**; Cocaine; Crack cocaine; Cardiovascular response; Blood pressure; Toxicity **57**, 239

**Heart rate**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Humans **59**, 261

**Hepatotoxicity**; Calcium sequestration; Cocaine; Ethanol; Lipid peroxidation **58**, 77

**Herbal dietary supplements**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Thermogenic agents **57**, 1

**Heroin**; Amphetamines; Harms; Injecting drug use **58**, 189

**Heroin**; Buprenorphine; Methadone maintenance; Addiction **60**, 39

**Heroin**; Crime reduction; Treatment outcome **58**, 165

**Heroin**; Delay discounting; Drug abuse; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

**Heroin**; Drug abuse; Drug dependence; Opiate dependence; Self-report; Urine testing **58**, 111

**Heroin**; Drug abuse treatment; Outpatient treatment; Aftercare; Cocaine; Contingency management; Housing; Employment **57**, 211

**Heroin**; Hostility; Retention; Early termination; Gender differences; Buprenorphine; Opioid dependence; Substance abuse treatment **58**, 27

**Heroin**; Methadone; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

**Heroin**; Opiate dependence; Cue; Neuroimaging **60**, 207

**Heroin-related deaths**; Morphine; Poldrug use **60**, 141

**Heroin treatment**; Alternate-day dosing; Buprenorphine; Buprenorphine–naloxone; Human; Methadone treatment **58**, 143

**Heroin treatment**; Methadone maintenance; Treatment retention **58**, 173

**High-school students**; Greece; Substance use; Trends **58**, 181

**HIV**; African-American; Alcohol; Crack; Sexual risk **58**, 259

**HIV/AIDS**; Drug abuse; Methadone maintenance treatment; Medicaid **60**, 77

**HIV/AIDS prevention**; Treatment; Methadone maintenance; Risk behavior **59**, 17

**HIV**; Brazil; Cocaine **58**, 267

**HIV**; Cocaine; Prevention initiatives **58**, 215

**HIV**; Crack; Injection drug user; Sex risk **58**, 219

**HIV**; Crack users **58**, 237

**HIV**; IDUs; Crack; Women **58**, 227

**HIV**; Injection drug users; Drug maintenance treatment; Viral load; Buprenorphine **60**, 51

**HIV prevention**; Drug abuse; AIDS; Antisocial personality; Depression; Comorbidity **58**, 247

**HIV-1 RNA load**; Injecting drug user; Blood; Needle/syringe; Paraphernalia; Shooting gallery; AIDS **58**, 153

**HIV status**; Endocrinology; Testosterone; Injection drug use **60**, 311

**Homeless**; Substance abuse; Cocaine; Treatment; Dual diagnosis **60**, 55

**Hostility**; Retention; Early termination; Gender differences; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

**Housing**; Drug abuse treatment; Outpatient treatment; Aftercare; Heroin; Cocaine; Contingency management; Employment **57**, 211

**Human**; Alternate-day dosing; Buprenorphine; Buprenorphine–naloxone; Heroin treatment; Methadone treatment **58**, 143

**Human**; Cocaine; Withdrawal; Outpatient; Drug dependence **59**, 277

**Humans**; Clozapine; Cocaine; Drug interactions **59**, 153

**Humans**; Ethanol; Taste perception; Bitter; Sweet; Sour **60**, 199

**Humans**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate **59**, 261

**Ibogaine**; MK-801; Dopamine; Corticosterone; Prolactin; Addiction **59**, 143

**IDUs**; Crack; HIV; Women **58**, 227

**Illegal drugs**; Alcohol; Road traffic accidents; Spain **57**, 177

**Illicit drugs**; Impaired driving; Impairment beliefs; Accident involvement **58**, 197

**Illicit drugs**; Medical students; Alcohol; Stress; Personality **59**, 125

**Immunology**; Morphine; Tolerance; Dependence; Macrophages; Phagocytosis **58**, 159

**Impaired driving**; Illicit drugs; Impairment beliefs; Accident involvement **58**, 197

**Impairment beliefs**; Illicit drugs; Impaired driving; Accident involvement **58**, 197

**Impulsivity**; Delay discounting; Drug abuse; Heroin; Needle sharing; Opioid; Self control; Delay discounting; Risky injection **60**, 259

**Impulsivity**; MDMA; Ecstasy; Serotonin; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

**Incentives**; Contingency management; Vouchers; Medication management; Compliance; Substance abuse treatment **58**, 9

**Indications**; Marijuana, medical uses; Compassionate use; Legal aspects; Questionnaire **58**, 3

**Injecting drug use**; Heroin; Amphetamines; Harms **58**, 189

**Injecting drug user**; Blood; Needle/syringe; Paraphernalia; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

**Injection drug use**; Endocrinology; Testosterone; HIV status **60**, 311

**Injection drug user**; HIV; Crack; Sex risk **58**, 219

**Injection drug users**; HIV; Drug maintenance treatment; Viral load; Buprenorphine **60**, 51

**Intravenous**; Brain imaging; Cocaine; Drug history; Safety **58**, 35

**Intravenous opioid treatment**; Heroin; Methadone; Cortical hemoglobin deoxygenation; Rush; Near infrared spectroscopy (NIRS); PROVE **57**, 23

**Khat**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Laboratory task**; Risk taking; Antisocial behavior; Drug abuse **60**, 179

**Legal aspects**; Marijuana, medical uses; Compassionate use; Indications; Questionnaire **58**, 3

**Lipid peroxidation**; Calcium sequestration; Cocaine; Ethanol; Hepatotoxicity **58**, 77

**Liver disease**; Alcoholism; Malnutrition; Social problems; Feeding habits; DEXA **59**, 295

**Liver**; *N*-acetylcysteine; Methanol-induced injury; Erythrocytes; Serum **57**, 61

**Lofexidine**; Naltrexone; Opiate detoxification **59**, 183

**Logistic models**; Epidemiologic factors; Residential mobility; Socioeconomic factors; Space-time clustering **57**, 183

**Lorazepam**; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Seizures; Side effects; Withdrawal **59**, 95

**Lymphocyte subsets**; Ethanol preference; Rats; Cytometry; Circadian cycle **60**, 303

**Macrophages**; Morphine; Tolerance; Dependence; Phagocytosis; Immunology **58**, 159

**Ma huang**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Major depression**; Cocaine dependence; Dual-diagnosis; Substance abuse comorbidity; Drug abuse **60**, 189

**Major depressive disorder**; Conduct disorder; Substance use; Attention-deficit hyperactivity disorder; Gender; Adolescents **59**, 131

**Malnutrition**; Alcoholism; Social problems; Feeding habits; Liver disease; DEXA **59**, 295

**Marijuana**; Cannabinoid; Dronabinol; Opioid; THC **59**, 251

**Marijuana, medical uses**; Compassionate use; Legal aspects; Indications; Questionnaire **58**, 3

**Marijuana smoking**; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

**MAST**; Alcohol consumption; CAGE; DOP system; Farm workers; South Africa **59**, 199

**MDMA**; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

**Medicaid**; HIV/AIDS; Drug abuse; Methadone maintenance treatment **60**, 77

**Medical students**; Alcohol; Illicit drugs; Stress; Personality **59**, 125

**Medication management**; Contingency management; Incentives; Vouchers; Compliance; Substance abuse treatment **58**, 9

**Mental disorder**; Smokers; Psychiatric diagnosis; Patch treatment; DSM-IV **60**, 267

**Mental health**; Moderate drinking; Psychosocial models; Cognitive performance; Alcohol consumption; Psychological benefits **60**, 221

**Meta-analysis**; Contingency management; Treatment efficacy; Methadone maintenance **58**, 55

**Metabolism**; Nicotine; Cotinine; Pharmacokinetics; Addiction; Tobacco; Pharmacodynamics **60**, 13

**Methadone**; Drug use; Overdose; Treatment; Suicide **58**, 117

**Methadone**; Heroin; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

**Methadone maintenance**; Buprenorphine; Heroin; Addiction **60**, 39

**Methadone maintenance clients**; Drug use frequency underreporting; Monte Carlo models; Hardcore drug use; Occasional drug use; Self-report **57**, 193

**Methadone maintenance**; Contingency management; Treatment efficacy; Meta-analysis **58**, 55

**Methadone maintenance**; HIV/AIDS prevention; Treatment; Risk behavior **59**, 17

**Methadone maintenance**; Parent training skills; Parent–child relationship **60**, 1

**Methadone maintenance treatment**; HIV/AIDS; Drug abuse; Medicaid **60**, 77

**Methadone maintenance**; Treatment retention; Heroin treatment **58**, 173

**Methadone**; Opioid; Overdose **57**, 247

**Methadone patients**; Voucher-based reinforcement; Abstinence initiation; Cocaine abuse; Urinalysis; Contingency contracting **58**, 205

**Methadone treatment**; Alternate-day dosing; Buprenorphine; Buprenorphine–naloxone; Heroin treatment; Human **58**, 143

**Methadone**; Treatment; Outcome; Response profiles **60**, 275

**Methadone**; Urinalysis; Self-report; Concordance; Validity **59**, 43

**Methamphetamine psychosis**; Flashbacks; Stressful experiences; Norepinephrine; 3-methoxytyramine **58**, 67

**Methanol-induced injury**; *N*-acetylcysteine; Liver; Erythrocytes; Serum **57**, 61

**Methohexital**; Drug self-administration; Propofol; Cocaine; Feeding; Primates; Abuse **57**, 51

**3-methoxytyramine**; Methamphetamine psychosis; Flashbacks; Stressful experiences; Norepinephrine **58**, 67

**MK-801**; Ibogaine; Dopamine; Corticosterone; Prolactin; Addiction **59**, 143

**Moderate drinking**; Psychosocial models; Mental health; Cognitive performance; Alcohol consumption; Psychological benefits **60**, 221

**Monte Carlo models**; Drug use frequency underreporting; Hardcore drug use; Occasional drug use; Self-report; Methadone maintenance clients **57**, 193

**Mood state**; Cue reactivity; Cocaine dependence; Craving; Cocaine use **59**, 33

**Morphine**; Heroin-related deaths; Poldrug use **60**, 141

**Morphine**; Nalmefene; Subjective effects; Blockade; Pharmacology **60**, 29

**Morphine**; Tolerance; Dependence; Macrophages; Phagocytosis; Immunology **58**, 159

**Motivation**; Treatment engagement; Program differences; Drug Abuse Treatment Outcome Studies **57**, 127

**Motivation**; Treatment process; Therapeutic engagements; Treatment retention; DATOS **57**, 113

**Multiple logistic regression analyses**; Residential treatment; 1 year outcomes **57**, 89

***N*-acetylcysteine**; Methanol-induced injury; Liver; Erythrocytes; Serum **57**, 61

**Nalmefene**; Morphine; Subjective effects; Blockade; Pharmacology **60**, 29

**Naloxone**; Dopamine; Nicotine; Abstinence; Nucleus accumbens; Prefrontal cortex **58**, 93

**Naltrexone**; Lofexidine; Opiate detoxification **59**, 183

**Naltrexone**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Subjective effects; Performance; Heart rate; Humans **59**, 261

**Naltrexone**; Opiate withdrawal; Trazodone; Clonidine **59**, 287

**Natural recoveries**; Autoremission; Drug use; Service utilization **59**, 211

**Near infrared spectroscopy (NIRS)**; Heroin; Methadone; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; PROVE **57**, 23

**Needle sharing**; Delay discounting; Drug abuse; Heroin; Impulsivity; Opioid; Self control; Delay discounting; Risky injection **60**, 259

**Needle/syringe**; Injecting drug user; Blood; Paraphernalia; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

**Neuroimaging**; Opiate dependence; Heroin; Cue **60**, 207

**Neurophysiology**; Ethanol; Abstinence; Associative learning; Event related potentials **58**, 125

**Neurotoxin**; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry **60**, 105

**Nicotine**; Cotinine; Metabolism; Pharmacokinetics; Addiction; Tobacco; Pharmacodynamics **60**, 13

**Nicotine**; Dopamine; Naloxone; Abstinence; Nucleus accumbens; Prefrontal cortex **58**, 93

**NMDA receptor antagonists**; Opiates; Psychostimulants; Alcohol; Pharmacotherapy **59**, 1

**Noradrenergic activity**; Alcohol withdrawal; Clonidine; Growth hormone **57**, 255

**Norephedrine**; Ephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Norepinephrine**; Methamphetamine psychosis; Flashbacks; Stressful experiences; 3-methoxytyramine **58**, 67

**Nosology**; Alcohol abuse; Alcohol dependence; Subtypes of alcohol dependence; Subtypes of alcohol abuse **60**, 287

**Nosology**; Alcohol dependence; Alcohol abuse; Dependence symptoms; Diagnosis **60**, 295

**Nucleus accumbens**; Dopamine; Nicotine; Naloxone; Abstinence; Prefrontal cortex **58**, 93

**Occasional drug use**; Drug use frequency underreporting; Monte Carlo models; Hardcore drug use; Self-report; Methadone maintenance clients **57**, 193

**Opiate dependence**; Drug abuse; Drug dependence; Heroin; Self-report; Urine testing **58**, 111

**Opiate dependence**; Heroin; Cue; Neuroimaging **60**, 207

**Opiate detoxification**; Lofexidine; Naltrexone **59**, 183

**Opiates**; NMDA receptor antagonists; Psychostimulants; Alcohol; Pharmacotherapy **59**, 1

**Opiate withdrawal**; Naltrexone; Trazodone; Clonidine **59**, 287

**Opioid**; Cannabinoid; Dronabinol; Marijuana; THC **59**, 251

**Opioid**; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Self control; Delay discounting; Risky injection **60**, 259

**Opioid dependence**; Buprenorphine; Treatment; Thrice-weekly dosing **59**, 223

**Opioid dependence**; Hostility; Retention; Early termination; Gender differences; Buprenorphine; Heroin; Substance abuse treatment **58**, 27

**Opioid**; Methadone; Overdose **57**, 247

**Opioids**; Detoxification; Addiction severity index **58**, 85

**Optical isomers**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Outcome measures**; DSM-IV dependence; Severity; Assessment; Reliability; Validity **59**, 63

**Outcome**; Methadone; Treatment; Response profiles **60**, 275

**Outpatient**; Cocaine; Withdrawal; Human; Drug dependence **59**, 277

**Outpatient treatment**; Drug abuse treatment; Aftercare; Heroin; Cocaine; Contingency management; Housing; Employment **57**, 211

**Overdose**; Drug use; Methadone; Treatment; Suicide **58**, 117

**Overdose**; Opioid; Methadone **57**, 247

**Panama**; Epidemiology; Drug use; Alternating logistic regression; Clustering; Schools **60**, 251

**Paranoia**; MDMA; Ecstasy; Serotonin; Impulsivity; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

**Paraphernalia**; Injecting drug user; Blood; Needle/syringe; Shooting gallery; HIV-1 RNA load; AIDS **58**, 153

**Parent–child relationship**; Methadone maintenance; Parent training skills **60**, 1

**Parent training skills**; Methadone maintenance; Parent–child relationship **60**, 1

**Patch treatment**; Smokers; Psychiatric diagnosis; Mental disorder; DSM-IV **60**, 267

**Performance**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Heart rate; Humans **59**, 261

**Pergolide**; Cocaine; Alcohol; Clinical trial; Pharmacotherapy **60**, 161

**Personality disorders**; Age of onset; Substance use disorders; Psychopathology; Comorbidity **59**, 305

**Personality**; Medical students; Alcohol; Illicit drugs; Stress **59**, 125

**Phagocytosis**; Morphine; Tolerance; Dependence; Macrophages; Immunology **58**, 159

**Pharmacodynamics**; Nicotine; Cotinine; Metabolism; Pharmacokinetics; Addiction; Tobacco **60**, 13

**Pharmacokinetics**; Nicotine; Cotinine; Metabolism; Addiction; Tobacco; Pharmacodynamics **60**, 13

**Pharmacology**; Nalmefene; Morphine; Subjective effects; Blockade **60**, 29

**Pharmacotherapy**; Cocaine; Pergolide; Alcohol; Clinical trial **60**, 161

**Pharmacotherapy**; NMDA receptor antagonists; Opiates; Psychostimulants; Alcohol **59**, 1

**Phenylpropanolamines**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**PI hydrolysis**; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Serotonin receptors; Dopamine receptors; Benzodiazepine receptors **60**, 121

**Poldrug use**; Heroin-related deaths; Morphine **60**, 141

**Postmarketing surveillance**; Tramadol HCl; Drug abuse; Drug dependence; Ultram®; Controlled Substances Act **57**, 7

**Predictive validity**; Substance Dependence Severity Scale; Assessment **59**, 77

**Prefrontal cortex**; Dopamine; Nicotine; Naloxone; Abstinence; Nucleus accumbens **58**, 93

**Prevention initiatives**; HIV; Cocaine **58**, 215

**Primates**; Drug self-administration; Propofol; Methohexital; Cocaine; Feeding; Abuse **57**, 51

**Program differences**; Treatment engagement; Motivation; Drug Abuse Treatment Outcome Studies **57**, 127

**Project MATCH**; Treatment matching; Generalizability; Exclusion criteria **59**, 177

**Prolactin**; Ibogaine; MK-801; Dopamine; Corticosterone; Addiction **59**, 143

**Propofol**; Drug self-administration; Methohexital; Cocaine; Feeding; Primates; Abuse **57**, 51

**PROVE**; Heroin; Methadone; Cortical hemoglobin deoxygenation; Rush; Intravenous opioid treatment; Near infrared spectroscopy (NIRS) **57**, 23

**Pseudoephedrine**; Ephedrine; Norephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements; Thermogenic agents **57**, 1

**Psychiatric diagnosis**; Smokers; Patch treatment; Mental disorder; DSM-IV **60**, 267

**Psychiatry**; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychobiology; Neurotoxin **60**, 105

**Psychobiology**; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychosis; Psychiatry; Neurotoxin **60**, 105

**Psychological benefits**; Moderate drinking; Psychosocial models; Mental health; Cognitive performance; Alcohol consumption **60**, 221

**Psychopathology**; Age of onset; Substance use disorders; Personality disorders; Comorbidity **59**, 305

**Psychosis**; MDMA; Ecstasy; Serotonin; Impulsivity; Paranoia; Psychobiology; Psychiatry; Neurotoxin **60**, 105

**Psychosocial models**; Moderate drinking; Mental health; Cognitive performance; Alcohol consumption; Psychological benefits **60**, 221

**Psychostimulants**; NMDA receptor antagonists; Opiates; Alcohol; Pharmacotherapy **59**, 1

**Questionnaire**; Marijuana, medical uses; Compassionate use; Legal aspects; Indications **58**, 3

**Race**; Reliability; Substance use disorders; Diagnosis **57**, 203

**Radioligand binding**; Cannabinoid; Cannabinoid receptors; Affinity; Cannabimimetic indoles; Aminoalkylindoles **60**, 133

**Rats**; Ethanol preference; Lymphocyte subsets; Cytometry; Circadian cycle **60**, 303

**Reference group**; Young adults; Drug use history; Treatment career; Self-efficacy **57**, 151

**Registered and unregistered alcohol consumption**; Russia; Alcohol consumption; Consequences of alcohol consumption **58**, 133

**Regression**; Epidemiology; Drug use; Stimulants **59**, 89

**Reinforcers**; Cognitive processes; Sequence **59**, 51

**Relapse**; Cigarette smoking; Contingency-management; Substance abuse; Schedules of reinforcement; Treatment **58**, 103

**Relapse**; Cocaine; Self-administration; Conditioned reinforcement; Extinction **57**, 41

**Relapse prevention**; Alcohol; Cue exposure; Dependent drinkers; Generalisation **57**, 29

**Relationships**; Aggression; Alcohol; Drugs; Violence **58**, 43

**Reliability**; DSM-IV dependence; Severity; Assessment; Validity; Outcome measures **59**, 63

**Reliability**; Substance use disorders; Race; Diagnosis **57**, 203

**Reliability**; Substance use reports; Agreement rates; Adolescents; Surveys **60**, 19

**Residential mobility**; Epidemiologic factors; Logistic models; Socioeconomic factors; Space-time clustering **57**, 183

**Residential treatment**; 1 year outcomes; Multiple logistic regression analyses **57**, 89

**Response profiles**; Methadone; Treatment; Outcome **60**, 275

**Retention**; Drug treatment; Treatment process; Counseling; Self-help groups **57**, 99

**Retention**; Hostility; Early termination; Gender differences; Buprenorphine; Heroin; Opioid dependence; Substance abuse treatment **58**, 27

**Risk behavior**; HIV/AIDS prevention; Treatment; Methadone maintenance **59**, 17

**Risk factor**; Drinking; Sustained smoking **59**, 235

**Risk factors**; Frequent smoking; Frequent drinking; Adolescent drug use; Substance use careers **60**, 319

**Risk taking**; Antisocial behavior; Drug abuse; Laboratory task **60**, 179

**Risky injection**; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Self control; Delay discounting **60**, 259

**Road traffic accidents**; Illegal drugs; Alcohol; Spain **57**, 177

**Rush**; Heroin; Methadone; Cortical hemoglobin deoxygenation; Intravenous opioid treatment; Near infrared spectroscopy (NIRS); PROVE **57**, 23

**Russia**; Alcohol consumption; Registered and unregistered alcohol consumption; Consequences of alcohol consumption **58**, 133

**Safety**; Brain imaging; Cocaine; Drug history; Intravenous **58**, 35

**Schedules of reinforcement**; Cigarette smoking; Contingency-management; Substance abuse; Relapse; Treatment **58**, 103

**Schools**; Epidemiology; Drug use; Panama; Alternating logistic regression; Clustering **60**, 251

**SCID**; Adolescents; Diagnostic interviews; DSM-IV; Substance use disorders **59**, 173

**Seizures**; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Side effects; Withdrawal **59**, 95

**Self-administration**; Adrenergic receptors; Carvedilol; Cocaine; Cardiovascular effects **60**, 69

**Self-administration**; Cocaine; Conditioned reinforcement; Extinction; Relapse **57**, 41

**Self control**; Delay discounting; Drug abuse; Heroin; Impulsivity; Needle sharing; Opioid; Delay discounting; Risky injection **60**, 259

**Self-efficacy**; Young adults; Drug use history; Treatment career; Reference group **57**, 151

**Self-help groups**; Alcoholics anonymous; Cocaine; Treatment; Drug abuse **60**, 169

**Self-help groups**; Drug treatment; Treatment process; Counseling; Retention **57**, 99

**Self-report**; Drug abuse; Drug dependence; Heroin; Opiate dependence; Urine testing **58**, 111

**Self-report**; Drug use frequency underreporting; Monte Carlo models; Hardcore drug use; Occasional drug use; Methadone maintenance clients **57**, 193

**Self-report**; Urinalysis; Concordance; Validity; Methadone **59**, 43

**Sequence**; Cognitive processes; Reinforcers **59**, 51

**Serotonin**; MDMA; Ecstasy; Impulsivity; Paranoia; Psychosis; Psychobiology; Psychiatry; Neurotoxin **60**, 105

**Serotonin receptors**; β-carbolines; Harmaline; Harmine; Hallucinogens; Dimethyltryptamine (DMT); 1-(2,5-Dimethoxy-4-methylphenyl)-2-aminopropane (DOM); Dopamine receptors; Benzodiazepine receptors; PI hydrolysis **60**, 121

**Serum**; *N*-acetylcysteine; Methanol-induced injury; Liver; Erythrocytes **57**, 61

**Service utilization**; Natural recoveries; Autoremission; Drug use **59**, 211

**Severity**; DSM-IV dependence; Assessment; Reliability; Validity; Outcome measures **59**, 63

**Sex risk**; HIV; Crack; Injection drug user **58**, 219

**Sexual risk**; African-American; Alcohol; Crack; HIV **58**, 259

**Shooting gallery**; Injecting drug user; Blood; Needle/syringe; Paraphernalia; HIV-1 RNA load; AIDS **58**, 153

**Side effects**; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Seizures; Withdrawal **59**, 95

**Smokers**; Psychiatric diagnosis; Patch treatment; Mental disorder; DSM-IV **60**, 267

**Social problems**; Alcoholism; Malnutrition; Feeding habits; Liver disease; DEXA **59**, 295

**Social support**; Drug treatment history; Treatment process; Treatment outcome; Environmental context; Cocaine use **57**, 137

**Socioeconomic factors**; Epidemiologic factors; Logistic models; Residential mobility; Space-time clustering **57**, 183

**Sour**; Ethanol; Taste perception; Bitter; Sweet; Humans **60**, 199

**South Africa**; Alcohol consumption; CAGE; MAST; DOP system; Farm workers **59**, 199

**Space-time clustering**; Epidemiologic factors; Logistic models; Residential mobility; Socioeconomic factors **57**, 183

**Spain**; Illegal drugs; Alcohol; Road traffic accidents **57**, 177

**Stimulants**; Epidemiology; Drug use; Regression **59**, 89

**Stressful experiences**; Methamphetamine psychosis; Flashbacks; Norepinephrine; 3-methoxytyramine **58**, 67

**Stress**; Medical students; Alcohol; Illicit drugs; Personality **59**, 125

**Student drinking**; Cross culture comparisons; Alcohol consumption *per capita* **60**, 315

**Subjective effects**; Marijuana smoking; $\Delta^9$-Tetrahydrocannabinol; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Performance; Heart rate; Humans **59**, 261

**Subjective effects**; Nalmefene; Morphine; Blockade; Pharmacology **60**, 29

**Substance abuse**; Cigarette smoking; Contingency-management; Relapse; Schedules of reinforcement; Treatment **58**, 103

**Substance abuse**; Cocaine; Treatment; Homeless; Dual diagnosis **60**, 55

**Substance abuse comorbidity**; Cocaine dependence; Major depression; Dual-diagnosis; Drug abuse **60**, 189

**Substance abuse**; Genotype–environment interaction; Behavioral phenotype **59**, 101

**Substance abuse treatment**; Contingency management; Incentives; Vouchers; Medication management; Compliance **58**, 9

**Substance abuse treatment**; Hostility; Retention; Early termination; Gender differences; Buprenorphine; Heroin; Opioid dependence **58**, 27

**Substance Dependence Severity Scale**; Assessment; Predictive validity **59**, 77

**Substance misuse**; Alcohol; Treatment outcomes; Evaluation; Clinical audit **59**, 189

**Substance use careers**; Frequent smoking; Frequent drinking; Risk factors; Adolescent drug use **60**, 319

**Substance use**; Conduct disorder; Attention-deficit hyperactivity disorder; Major depressive disorder; Gender; Adolescents **59**, 131

**Substance use disorders**; Adolescents; Diagnostic interviews; DSM-IV; SCID **59**, 173

**Substance use disorders**; Age of onset; Personality disorders; Psychopathology; Comorbidity **59**, 305

**Substance use disorders**; Reliability; Race; Diagnosis **57**, 203

**Substance use**; Greece; High-school students; Trends **58**, 181

**Substance use reports**; Agreement rates; Reliability; Adolescents; Surveys **60**, 19

**Subtypes of alcohol abuse**; Alcohol abuse; Alcohol dependence; Subtypes of alcohol dependence; Nosology **60**, 287

**Subtypes of alcohol dependence**; Alcohol abuse; Alcohol dependence; Subtypes of alcohol abuse; Nosology **60**, 287

**Suicide**; Drug use; Overdose; Methadone; Treatment **58**, 117

**Survey methods**; AUDIT; Epidemiology **60**, 97

**Surveys**; Substance use reports; Agreement rates; Reliability; Adolescents **60**, 19

**Sustained smoking**; Drinking; Risk factor **59**, 235

**Sweet**; Ethanol; Taste perception; Bitter; Sour; Humans **60**, 199

**Taste perception**; Ethanol; Bitter; Sweet; Sour; Humans **60**, 199

**Testosterone**; Endocrinology; HIV status; Injection drug use **60**, 311

**$\Delta^9$-Tetrahydrocannabinol**; Marijuana smoking; Antinociception; Analgesia; Endogenous opioids; Naltrexone; Subjective effects; Performance; Heart rate; Humans **59**, 261

**THC**; Cannabinoid; Dronabinol; Marijuana; Opioid **59**, 251

**$\Delta^9$-THC**; Delta-9-tetrahydrocannabinol; Cannabinoid; Tolerance; Time course **60**, 113

**Therapeutic engagements**; Treatment process; Treatment retention; Motivation; DATOS **57**, 113

**Thermogenic agents**; Ephedrine; Norephedrine; Pseudoephedrine; Cathine; Phenylpropanolamines; Amphetamine; Khat; Ma huang; Optical isomers; Ephedra; Herbal dietary supplements **57**, 1

**Thrice-weekly dosing**; Buprenorphine; Opioid dependence; Treatment **59**, 223

**Time course**; Delta-9-tetrahydrocannabinol; $\Delta^9$-THC; Cannabinoid; Tolerance **60**, 113

**Tobacco**; Nicotine; Cotinine; Metabolism; Pharmacokinetics; Addiction; Pharmacodynamics **60**, 13

**Tolerance**; Delta-9-tetrahydrocannabinol; $\Delta^9$-THC; Cannabinoid; Time course **60**, 113

**Tolerance**; Morphine; Dependence; Macrophages; Phagocytosis; Immunology **58**, 159

**Toxicity**; Cocaine; Crack cocaine; Cardiovascular response; Blood pressure; Heart rate **57**, 239

**Tramadol HCl**; Drug abuse; Drug dependence; Ultram®; Postmarketing surveillance; Controlled Substances Act **57**, 7

**Trazodone**; Opiate withdrawal; Naltrexone; Clonidine **59**, 287

**Treatment benefits**; Drug treatment costs; Crime costs; Cocaine addiction; Cost-benefit **57**, 167

**Treatment**; Buprenorphine; Opioid dependence; Thrice-weekly dosing **59**, 223

**Treatment career**; Young adults; Drug use history; Self-efficacy; Reference group **57**, 151

**Treatment**; Cigarette smoking; Contingency-management; Substance abuse; Relapse; Schedules of reinforcement **58**, 103

**Treatment**; Drug use; Overdose; Methadone; Suicide **58**, 117

**Treatment efficacy**; Contingency management; Methadone maintenance; Meta-analysis **58**, 55

**Treatment engagement**; Motivation; Program differences; Drug Abuse Treatment Outcome Studies **57**, 127

**Treatment**; HIV/AIDS prevention; Methadone maintenance; Risk behavior **59**, 17

**Treatment matching**; Project MATCH; Generalizability; Exclusion criteria **59**, 177

**Treatment**; Methadone; Outcome; Response profiles **60**, 275

**Treatment outcome**; Cocaine dependence; Baseline predictors **59**, 215

**Treatment outcome**; Crime reduction; Heroin **58**, 165

**Treatment outcome**; Drug treatment history; Treatment process; Social support; Environmental context; Cocaine use **57**, 137

**Treatment outcomes**; Substance misuse; Alcohol; Evaluation; Clinical audit **59**, 189

**Treatment process**; DATOS; Cost-benefit model **57**, 81

**Treatment process**; Drug treatment; Counseling; Self-help groups; Retention **57**, 99

**Treatment process**; Drug treatment history; Treatment outcome; Social support; Environmental context; Cocaine use **57**, 137

**Treatment process**; Therapeutic engagements; Treatment retention; Motivation; DATOS **57**, 113

**Treatment retention**; Methadone maintenance; Heroin treatment **58**, 173

**Treatment retention**; Treatment process; Therapeutic engagements; Motivation; DATOS **57**, 113

**Treatment**; Self-help groups; Alcoholics anonymous; Cocaine; Drug abuse **60**, 169

**Treatment**; Substance abuse; Cocaine; Homeless; Dual diagnosis **60**, 55

**Treatment**; Washington State; Employment **60**, 151

**Trends**; Greece; High-school students; Substance use **58**, 181

**Twin study**; Drug and alcohol abuse; Genetics **57**, 69

**Ultram®**; Tramadol HCl; Drug abuse; Drug dependence; Postmarketing surveillance; Controlled Substances Act **57**, 7

**Urinalysis**; Self-report; Concordance; Validity; Methadone **59**, 43

**Urinalysis**; Voucher-based reinforcement; Abstinence initiation; Cocaine abuse; Methadone patients; Contingency contracting **58**, 205

**Urine testing**; Drug abuse; Drug dependence; Heroin; Opiate dependence; Self-report **58**, 111

**Validity**; DSM-IV dependence; Severity; Assessment; Reliability; Outcome measures **59**, 63

**Validity**; Urinalysis; Self-report; Concordance; Methadone **59**, 43

**Violence**; Aggression; Relationships; Alcohol; Drugs **58**, 43

**Viral load**; HIV; Injection drug users; Drug maintenance treatment; Buprenorphine **60**, 51

**Voucher-based reinforcement**; Abstinence initiation; Cocaine abuse; Urinalysis; Methadone patients; Contingency contracting **58**, 205

**Vouchers**; Contingency management; Incentives; Medication management; Compliance; Substance abuse treatment **58**, 9

**Washington State**; Treatment; Employment **60**, 151

**Withdrawal**; Benzodiazepine; Convulsive status epilepticus; Flunitrazepam; Lorazepam; Seizures; Side effects **59**, 95

**Withdrawal**; Cocaine; Human; Outpatient; Drug dependence **59**, 277

**Women**; Anabolic-androgenic steroids; Abuse; Dependence **60**, 91

**Women**; IDUs; Crack; HIV **58**, 227

**1 year outcomes**; Residential treatment; Multiple logistic regression analyses **57**, 89

**Young adults**; Drug use history; Treatment career; Self-efficacy; Reference group **57**, 151